Condition
Alzheimer's Disease Clinical Trials
Studies of alzheimer's disease, matched by condition name and medical subject headings. Start with those open to enrolment.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 864Alzheimer Disease
[18F]PI-2620 Phase 3 Histopathological Study
This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with [18F]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and…
- Trial name
- NCT05641688
- Testing
- [18F]PI-2620
- Where
- 25 sites in United States
- Volunteers
- 200 people
- Sponsor
- Lantheus Biosciences Ltd.
Aging
Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging
Background: Some people experience cognitive decline as they age. That is, they lose memory, problem-solving, and other mental abilities.
- Trial name
- NCT07099053
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Alzheimer s Disease, Mild Cognitive Impairment
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Background: About 5 million adults in the United States have age-related brain disorders. These include Alzheimer disease (AD), mild cognitive impairment (MCI), and other dementias.
- Conditions
- Alzheimer s Disease, Mild Cognitive Impairment, Healthy
- Trial name
- NCT07169630
- Testing
- 18F-PF974, 18F-florbetaben
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Dementia, Alzheimer's Type, Alzheimer's Disease
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
This is a randomized, placebo-controlled Phase 2 study to evaluate the efficacy and safety of SAR448851 in early Alzheimer's disease (AD) participants.
- Trial name
- TREMHANCE (NCT07688213)
- Testing
- SAR448851
- Where
- 20 sites in United States, Australia and 4 more
- Volunteers
- 160 people
- Sponsor
- Sanofi
Alzheimer's Disease
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Background: Normal aging, as well as dementias such as Alzheimer s disease, can cause changes in the brain that affect memory, attention, and thinking.
- Trial name
- NCT07721467
- Testing
- Psilocybin, Cognitive Training
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Dementia, Alzheimer Dementia (AD)
Fuzhou Aging Brain Health Initiative
The goal of this observational study is to learn about the pathophysiological characterization and evolutionary patterns of Alzheimer's disease (AD) in older adults in Fujian Province, China.
- Conditions
- Dementia, Alzheimer Dementia (AD), Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)
- Trial name
- FAITH (NCT07891429)
- Testing
- Fluids biomarker and neuroimaging of AD diagnosis
- Where
- 4 sites in China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Fujian Medical University Union Hospital
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including…
- Conditions
- Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- MERIT (NCT07892651)
- Where
- Jordan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Axiom Bioregistry
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
InRAD Observational Study
The goal of this international observational study is to evaluate long-term disease outcomes and treatment safety in people with Alzheimer's disease (PwAD), by collecting real-world data from routine clinical practice across…
- Conditions
- Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD), Non-Alzheimer Degenerative Dementia
- Trial name
- InRAD (NCT07213700)
- Testing
- None, this is a non-interventional observational study
- Where
- 23 sites in Australia, Austria and 15 more
- Volunteers
- 50,000 people
- Sponsor
- Stichting International Registry for Alzheimer's Disease and other Dementias Foundation
Mild Cognitive Impairment, Alzheimer's Disease
Use of Wearables for Identifying Factors Associated With Mild Cognitive Impairment and Early-Stage Alzheimer's Disease
Cognitive decline affects millions of older adults worldwide and has a profound impact on individuals, families, and healthcare systems.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease Dementia
- Trial name
- NCT07391436
- Where
- Brazil
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Getúlio Vargas University Hospital
Healthy Volunteers, Alzheimer Disease
A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
The purpose of this study is to see how safe LY4405094 is and to see how much and how quickly LY4405094 gets into the bloodstream.
- Conditions
- Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
- Trial name
- NCT07787182
- Testing
- LY4405094, Florbetapir F18, Florbetaben F 18
- Where
- 18 sites in United States, China and 1 more
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company